{"id":15289,"date":"2021-08-26T10:16:40","date_gmt":"2021-08-26T08:16:40","guid":{"rendered":"https:\/\/convergences.online\/hemato\/?p=15289"},"modified":"2021-08-26T10:16:40","modified_gmt":"2021-08-26T08:16:40","slug":"incyte-et-morphosys-annoncent-avoir-recu-lapprobation-de-la-commission-europeenne-pour-minjuvi-tafasitamab-en-association-avec-le-lenalidomide-dans-le-traitement-des-adultes-atteints","status":"publish","type":"post","link":"https:\/\/www.hematostat.net\/en\/incyte-et-morphosys-annoncent-avoir-recu-lapprobation-de-la-commission-europeenne-pour-minjuvi-tafasitamab-en-association-avec-le-lenalidomide-dans-le-traitement-des-adultes-atteints\/","title":{"rendered":"Incyte et MorphoSys annoncent avoir re\u00e7u l\u2019approbation de la Commission europ\u00e9enne pour Minjuvi\u00ae (tafasitamab) en association avec le l\u00e9nalidomide dans le traitement des adultes atteints d\u2019un lymphome diffus \u00e0 grandes cellules B en rechute ou r\u00e9fractaire"},"content":{"rendered":"

– La d\u00e9cision de la Commission europ\u00e9enne s\u2019appuie sur les donn\u00e9es de l\u2019\u00e9tude L-MIND \u00e9valuant Minjuvi\u00ae<\/strong>en association avec le l\u00e9nalidomide pour le traitement des patients atteints d\u2019un LDGCB en rechute ou r\u00e9fractaire.<\/p>\n

– Minjuvi\u00ae<\/strong>est une nouvelle option th\u00e9rapeutique pour les patients \u00e9ligibles atteints de LDGCB dans l\u2019Union europ\u00e9enne (UE) et r\u00e9pond \u00e0 un besoin m\u00e9dical non satisfait urgent.<\/p>\n

– En Europe, environ 16 000 patients ont chaque ann\u00e9e un diagnostic de LDGCB en rechute ou r\u00e9fractaire(1,2,3)<\/sup>.<\/p>\n

Ces r\u00e9sultats reposent sur l’\u00e9tude L-MIND qui est une \u00e9tude de phase 2, en ouvert, \u00e0 bras unique (NCT02399085), qui \u00e9tudie l\u2019association du tafasitamab et du l\u00e9nalidomide chez des patients atteints d\u2019un lymphome diffus \u00e0 grandes cellules B (LDGCB) en rechute ou r\u00e9fractaire, apr\u00e8s au minimum une ligne et au maximum trois lignes de traitement ant\u00e9rieures, incluant une th\u00e9rapie cibl\u00e9e anti-CD20 (par ex. rituximab), qui ne sont pas \u00e9ligibles \u00e0 une chimioth\u00e9rapie \u00e0 haute dose (CHD) suivie d\u2019une autogreffe de cellules souches h\u00e9matopo\u00ef\u00e9tiques. Le crit\u00e8re d\u2019\u00e9valuation principal de l\u2019\u00e9tude est le taux de r\u00e9ponse globale (TRG). Les crit\u00e8res d\u2019\u00e9valuation secondaires comprennent la dur\u00e9e de r\u00e9ponse (DR), la survie sans progression (SSP) et la survie globale (SG). L\u2019analyse primaire de l\u2019\u00e9tude date de mai 2019.<\/p>\n

Incyte d\u00e9tient les droits exclusifs de commercialisation pour Minjuvi\u00ae<\/strong>en dehors des \u00c9tats-Unis.<\/p>\n

    \n
  1. Donn\u00e9es \u00e9pid\u00e9miologiques du DRG. <\/em><\/li>\n
  2. \u00c9tude de march\u00e9 de Kantar (tests TPP 2018). <\/em><\/li>\n
  3. Friedberg, Jonathan W. Relapsed\/Refractory Diffuse Large B-Cell Lymphoma. <\/em>Hematology Am Soc Hematol Educ Program 2011; 2011:498-505. doi: 10.1182\/asheducation-2011.1.498.<\/em><\/li>\n<\/ol>\n

    D’apr\u00e8s un communiqu\u00e9 de presse de Incyte et MorphoSys, le 26 ao\u00fbt 2021.<\/em><\/p>\n<\/div><\/div><\/div><\/div><\/div>","protected":false},"excerpt":{"rendered":"","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"_uf_show_specific_survey":0,"_uf_disable_surveys":false,"footnotes":""},"categories":[21],"tags":[],"ppma_author":[442],"class_list":["post-15289","post","type-post","status-publish","format-standard","hentry","category-communique-de-presse","author-marion"],"aioseo_notices":[],"authors":[{"term_id":442,"user_id":2,"is_guest":0,"slug":"marion","display_name":"HematoStat.net (M)","avatar_url":{"url":"https:\/\/www.hematostat.net\/wp-content\/uploads\/2024\/01\/favicon-hematoStat.png","url2x":"https:\/\/www.hematostat.net\/wp-content\/uploads\/2024\/01\/favicon-hematoStat.png"},"first_name":"HematoStat.net (M)","last_name":"","user_url":"","description":""}],"_links":{"self":[{"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/posts\/15289","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/comments?post=15289"}],"version-history":[{"count":0,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/posts\/15289\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/media?parent=15289"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/categories?post=15289"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/tags?post=15289"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/ppma_author?post=15289"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}